Physiologically‐based pharmacokinetic modeling of pantoprazole to evaluate the role of <scp>CYP2C19</scp> genetic variation and obesity in the pediatric population
Elizabeth J. Thompson(University of North Carolina at Chapel Hill), Daniel González(University of North Carolina at Chapel Hill), Victória Etges Helfer(University of North Carolina at Chapel Hill), Angela Jeong(University of Minnesota), Ravinder Anand(Population Health Research Institute), Laura P. James(University of Arkansas for Medical Sciences), Valentina Shakhnovich(Ironwood Pharmaceuticals (United States)), Stephen J. Balevic(Duke University), David N. Collier(East Carolina University), Andrea N. Edginton(University of Waterloo)
Cited by 5
Related Papers
Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics
|Journal of Pharmaceutical Sciences|2009|337
Soil and Human Health: Current Status and Future Needs
|Air Soil and Water Research|2020|317
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
|Clinical Infectious Diseases|2020|232
Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic
|Obesity|2021|199
Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing
|Clinical Therapeutics|2016|170